Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
about
Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participateTarget of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsReviewing 15 years of experience with sirolimusRenal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.Effectiveness and safety of calcineurin inhibitor withdrawal in kidney transplantation: a meta-analysis of randomized controlled trials.Sirolimus is associated with new-onset diabetes in kidney transplant recipients.Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors.Current and future immunosuppressive strategies in renal transplantation.Strategies for minimizing immunosuppression in kidney transplantation.Clinical application of sirolimus in renal transplantation: an update.Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials.Single-dose daclizumab induction therapy in patients with liver transplantation.Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.Sirolimus: its role in nephrology.Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial.Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia.The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.Biochemical mechanisms of nephrotoxicity: application for metabolomics.Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function.Is it time to give up with calcineurin inhibitors in kidney transplantation?Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysisThrough a glass darkly: seeking clarity in preventing late kidney transplant failureSafety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth.The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow UpConversion to sirolimus in pediatric renal transplant patients: a single-center experience.Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction.Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States.Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing.Long-term immunosuppression, without maintenance prednisone, after kidney transplantation.Effect of sirolimus withdrawal in patients with deteriorating renal function.Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience.Cyclosporine A effectively inhibits graft-versus-host disease during development of Epstein-Barr virus-infected human B cell lymphoma in SCID mouse.The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.
P2860
Q24242288-8580074E-B691-48BA-A7C0-DE21B6E62640Q24246340-FB4A195C-D435-42E4-8110-5EE6B7D8466DQ28080955-CB7C1020-1493-46B2-BD28-904FCE631085Q30275870-1EE93D5E-03FB-4334-B8AF-64592B7B9298Q33376348-DE087902-7041-470C-A095-9CAF73CD7470Q33421541-D3B2418D-A7F7-4B10-AE0F-99FB945D7935Q34767143-9E311DBD-1D4C-4A40-96E1-BEEF3EE432BDQ35819373-FB1A23F4-D472-41F9-8488-FD7753BF242BQ35841386-0FCE9F97-E4B0-43EC-A59B-061C8721ED53Q35906315-75C45C72-4040-4A4F-A76C-281BF8E6D72BQ35990853-9884E361-E8B8-4CA5-A09C-0055F7234228Q36054093-B62727DB-9F74-4AE4-B3C0-977CDB9003F3Q36155850-E102F79F-C50F-4BE7-A84C-0C98E55D4C97Q36179019-EDBD8BBC-5691-411F-9E85-30C0997ADE2AQ36314978-28C49C2B-9D3E-4B13-8C64-30393E834459Q36341793-F9A180A2-B868-4099-B717-41F30DF63F20Q36498564-E3AB2FD3-EED4-44EA-8C03-788691D21CB7Q36536752-174AF239-B7E7-43F9-BA9C-66DAAB89CE49Q36742547-9F02D1F8-ABA2-4066-A2BF-363A2DE99EE5Q36909319-562810F4-36B6-47A8-880D-CC70233FFB27Q37105132-A9B38528-B54E-48BC-864A-DC97B83B62F6Q38156847-3155F107-B140-4E26-BDDB-982D90A67068Q38164111-16093A2D-2F86-4C46-9E8E-23A1B8E52B09Q38237365-8623FAA7-4415-4F0D-8D5F-E340ACEA8A86Q38268775-9AE42150-86D9-411B-93CD-683678E34A25Q38668601-5E84C4CC-FE41-4903-A420-90867CFF6896Q38779769-77D4D780-FEC7-4F58-81CD-047E63F1DAFBQ38914374-582A0669-7EEE-4C4F-BF7A-70F061CF70B2Q40446087-D1CEED8B-0239-44AE-A2A0-5938A34B624DQ42517229-A094E80B-EE6D-4B64-8E42-4598F92C1440Q42612170-AEA21AE6-F155-4886-AF1B-7002F6CCF9D5Q43808149-B71FAAA1-C472-48DF-ABE6-11C3F75C1FD2Q44448395-0D8AE3C8-62CF-48BF-BFCD-0A36AC2FB3AEQ44981183-C07EC85C-7CBB-4459-BB3C-01F32C3C6503Q44989320-26288356-BD85-4936-B430-707F102744A8Q45023761-6D2FE9E1-CD50-48A7-A75B-867D4BF9E32DQ45058867-9EBAE112-C105-4C69-989E-9FB5641724AAQ45250853-1864F7B7-2652-42F4-9781-1DFCECDD6872Q45721862-103026CF-E59E-4E93-8564-BB4CB07FC08EQ46233987-DFA9E29D-AF48-4939-BC38-2CBFED20C7C7
P2860
Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Improved renal function in sir ...... arly cyclosporine elimination.
@ast
Improved renal function in sir ...... arly cyclosporine elimination.
@en
type
label
Improved renal function in sir ...... arly cyclosporine elimination.
@ast
Improved renal function in sir ...... arly cyclosporine elimination.
@en
prefLabel
Improved renal function in sir ...... arly cyclosporine elimination.
@ast
Improved renal function in sir ...... arly cyclosporine elimination.
@en
P2093
P1433
P1476
Improved renal function in sir ...... arly cyclosporine elimination.
@en
P2093
Donald E Hricik
Francesco P Schena
Josep M Grinyo
Karl Brinker
Sirolimus Renal Function Study Group
Thomas A Gonwa
P304
P356
10.1097/00007890-200212150-00013
P577
2002-12-01T00:00:00Z